{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:30:57Z","timestamp":1792614657053,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anti TNF\u03b1 agents can induce cutaneous adverse events in both adults and children. While drug-related alopecia was reported in adults treated with TNF\u03b1 inhibitors for various indications, pediatric data are scarce. To describe clinical characteristics and outcomes in pediatric patients with TNF\u03b1 inhibitor-induced alopecia we conducted a single center retrospective study (0748-21-RMC, retrospectively registered on January 2nd 2022) including all patients aged\u2009&lt;\u200918\u00a0years who were treated with TNF\u03b1 inhibitors for any indication and developed drug-induced alopecia between the years 2018\u20132023. A\u00a0comprehensive literature review was also performed. Twenty patients were included (mean age 12.9\u2009\u00b1\u20093.1\u00a0years, male:female ratio 1:1.4). Fourteen were diagnosed with Crohn\u2019s disease, three with ulcerative colitis, and three with juvenile idiopathic arthritis. Half of the patients were treated with adalimumab and half with infliximab. Overall, alopecia was observed after 14.8\u2009\u00b1\u200910.8\u00a0months of treatment. Eighteen (90.0%) patients presented with psoriatic-like inflammatory alopecia, and two with alopecia areata-like lesions. Seventeen (85.0%) patients discontinued their anti-TNF\u03b1 therapy due to the alopecia, all presented hair regrowth within six months. Hair regrowth was not recorded in three patients who continued TNF\u03b1 inhibitors. Literature review of pediatric TNF\u03b1 inhibitor-induced alopecia revealed comparable patients\u2019 demographics and response to treatment discontinuation. In conclusion, TNF\u03b1 inhibitor-induced alopecia is a rare adverse event in children, occurring mainly in adolescents with inflammatory bowel diseases. Our relatively large cohort provides further evidence for the need for TNF\u03b1 inhibitor cessation to improve drug-induced alopecia in pediatric patients.    <\/jats:p>","DOI":"10.1007\/s00403-025-04300-0","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T16:40:34Z","timestamp":1749228034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor necrosis factor \u03b1 inhibitor-induced alopecia in pediatric patients: a cohort of 20 patients and review of the literature"],"prefix":"10.1007","volume":"317","author":[{"given":"Shiran","family":"Reiss-Huss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hilewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Yacobovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Matar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror S.","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chani","family":"Topf-Olivestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Amarilyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Renert-Yuval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-3656","authenticated-orcid":false,"given":"Rivka","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"4300_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/rheumatology\/keu145","volume":"53","author":"J B\u00e9n\u00e9","year":"2014","unstructured":"B\u00e9n\u00e9 J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P et al (2014) Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford) 53:1465\u20131469","journal-title":"Rheumatology (Oxford)"},{"key":"4300_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.36849\/JDD.2020.2106","volume":"19","author":"L Bonomo","year":"2020","unstructured":"Bonomo L, de Moll EH, Li L, Geller L, Gordon MI, Dunkin D (2020) Tumor necrosis factor inhibitor-induced psoriasis in a pediatric crohn\u2019s disease patient successfully treated with ustekinumab. J Drugs Dermatol 19:328\u2013333","journal-title":"J Drugs Dermatol"},{"key":"4300_CR3","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","volume":"84","author":"CL Boull","year":"2021","unstructured":"Boull CL, Gardeen S, Abdali T, Li E, Potts J, Rubin N et al (2021) Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study. J Am Acad Dermatol 84:1554\u20131561","journal-title":"J Am Acad Dermatol"},{"key":"4300_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jdcr.2018.06.008","volume":"4","author":"JA Campbell","year":"2018","unstructured":"Campbell JA, Kodama SS, Gupta D, Zhao Y (2018) Case series of psoriasis associated with tumor necrosis factor-\u03b1 inhibitors in children with chronic recurrent multifocal osteomyelitis. JAAD Case Rep 4:767\u2013771","journal-title":"JAAD Case Rep"},{"key":"4300_CR5","first-page":"E48","volume":"107","author":"OY Carrasquillo","year":"2021","unstructured":"Carrasquillo OY, Pab\u00f3n-Cartagena G, Barrera-Llaurador J, Col\u00f3n-Fontanez F, Mart\u00edn-Garc\u00eda RF (2021) psoriatic alopecia in a patient with crohn disease: an uncommon manifestation of tumor necrosis factor \u03b1 inhibitors. Cutis 107:E48\u2013E55","journal-title":"Cutis"},{"key":"4300_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjac055","volume":"16","author":"MT Dolinger","year":"2022","unstructured":"Dolinger MT, Rolfes P, Spencer E, Stoffels G, Dunkin D, Dubinsky MC (2022) Outcomes of children with inflammatory bowel disease who develop anti-tumour necrosis factor-induced skin reactions. J Crohns Colitis 16:1420\u20131427","journal-title":"J Crohns Colitis"},{"key":"4300_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/DAD.0b013e3181ef7403","volume":"33","author":"LA Doyle","year":"2011","unstructured":"Doyle LA, Sperling LC, Baksh S, Lackey J, Thomas B, Vleugels RA et al (2011) Psoriatic alopecia\/alopecia areata-like reactions secondary to anti-tumor necrosis factor-\u03b1 therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol 33:161\u2013166","journal-title":"Am J Dermatopathol"},{"key":"4300_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/pde.13081","volume":"34","author":"JB Eickstaedt","year":"2017","unstructured":"Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM (2017) Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol 34:253\u2013260","journal-title":"Pediatr Dermatol"},{"key":"4300_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","volume":"159","author":"J Eickstaedt","year":"2023","unstructured":"Eickstaedt J, Paller AS, Lund E, Murphrey M, Brandling-Bennett H, Maurano M et al (2023) Paradoxical psoriasiform eruptions in children receiving tumor necrosis factor \u03b1 inhibitors. JAMA Dermatol 159:637\u2013642","journal-title":"JAMA Dermatol"},{"key":"4300_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1468-3083.2010.03770.x","volume":"25","author":"M Ferran","year":"2011","unstructured":"Ferran M, Calvet J, Almirall M, Pujol RM, Maym\u00f3 J (2011) Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-\u03b1 blocker agents: Report of five cases and review of the literature. J Eur Acad Dermatol Venereol 25:479\u2013484","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4300_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1159\/000539374","volume":"240","author":"R Friedland","year":"2024","unstructured":"Friedland R, Glick M, Amitay-Laish I, Toledano H (2024) Cutaneous reactions in pediatric patients treated with MEK inhibitors: a retrospective single-center study. Dermatology 240:565\u2013571","journal-title":"Dermatology"},{"issue":"40","key":"4300_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/ced.12715","volume":"20","author":"SM George","year":"2015","unstructured":"George SM, Taylor MR, Farrant PB (2015) Psoriatic alopecia. Clin Exp Dermatol 20(40):717\u2013721","journal-title":"Clin Exp Dermatol"},{"key":"4300_CR13","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/pde.14993","volume":"39","author":"T Goldberger","year":"2022","unstructured":"Goldberger T, Benshushan S, Davidovics Z, Wilschanski M, Molho-Pessach V (2022) Tumor necrosis factor-\u03b1 inhibitor-induced follicular psoriasiform eruption. Pediatr Dermatol 39:598\u2013600","journal-title":"Pediatr Dermatol"},{"key":"4300_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/pde.13859","volume":"36","author":"D Groth","year":"2019","unstructured":"Groth D, Perez M, Treat JR, Castelo-Soccio L, Nativ S, Weiss PF et al (2019) Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis in juvenile idiopathic arthritis patients. Pediatr Dermatol 36:613\u2013617","journal-title":"Pediatr Dermatol"},{"key":"4300_CR15","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. [cited 2024 Jun 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103772s5301lbl.pdf"},{"key":"4300_CR16","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. [cited 2024 Jun 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125057s423lbl.pdf"},{"issue":"2","key":"4300_CR17","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1111\/pde.12768","volume":"33","author":"PS Jayasekera","year":"2016","unstructured":"Jayasekera PS, Walsh ML, Hurrell D, Parslew RA (2016) Case report of lichen planopilaris occurring in a pediatric patient receiving a tumor necrosis factor \u03b1 inhibitor and a review of the literature. Pediatr Dermatol 33(2):e143\u2013e146","journal-title":"Pediatr Dermatol"},{"key":"4300_CR18","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1111\/jdv.12009","volume":"27","author":"NM Luk","year":"2013","unstructured":"Luk NM, Chiu LS, Lee KC, Chau CT, Lee VW, Chang M et al (2013) Efficacy and safety of diphenylcyclopropenone among Chinese patients with steroid resistant and extensive alopecia areata. J Eur Acad Dermatol Venereol 27:e400\u2013e405","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"4300_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.medcli.2024.09.004","volume":"164","author":"CMC Magalh\u00e3es","year":"2025","unstructured":"Magalh\u00e3es CMC, Bartholo MR, Correa BHM, Ferrari MLA, Ferrari TCA (2025) Dermatoses in patients with inflammatory bowel disease under tumor necrosis factor-alpha inhibitors treatment. Med Clin (Barc) 164(4):173\u2013177","journal-title":"Med Clin (Barc)"},{"key":"4300_CR20","doi-asserted-by":"publisher","first-page":"2050313X2090196","DOI":"10.1177\/2050313X20901967","volume":"8","author":"ML McPhie","year":"2020","unstructured":"McPhie ML, Wang A, Molin S, Herzinger T (2020) Lichen planopilaris induced by infliximab: a case report. SAGE Open Med Case Rep 8:2050313X20901967","journal-title":"SAGE Open Med Case Rep"},{"key":"4300_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000342503","volume":"225","author":"F Os\u00f3rio","year":"2012","unstructured":"Os\u00f3rio F, Magro F, Lisboa C, Lopes S, Macedo G, Bettencourt H et al (2012) Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology 225:163\u2013167","journal-title":"Dermatology"},{"key":"4300_CR22","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1007\/s10620-024-08575-7","volume":"69","author":"Y Pan","year":"2024","unstructured":"Pan Y, Lilly E, Ananthakrishnan AN (2024) Risk factors for the development of and outcomes after diagnosis of autoimmune alopecia areata in patients with inflammatory bowel diseases. Dig Dis Sci 69:3375\u20133381","journal-title":"Dig Dis Sci"},{"key":"4300_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1525-1470.2011.01521.x","volume":"29","author":"MJ Perman","year":"2012","unstructured":"Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW (2012) Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol 29:454\u2013459","journal-title":"Pediatr Dermatol"},{"key":"4300_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/ijd.17014","volume":"63","author":"A Ravipati","year":"2024","unstructured":"Ravipati A, Pradeep T, Tosti A (2024) A cross-sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system. Int J Dermatol 63:497\u2013502","journal-title":"Int J Dermatol"},{"key":"4300_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1590\/abd1806-4841.20153084","volume":"90","author":"LB Ribeiro","year":"2015","unstructured":"Ribeiro LB, Rego JC, Estrada BD, Bastos PR, Pi\u00f1eiro Maceira JM, Sodr\u00e9 CT (2015) Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol 90:232\u2013235","journal-title":"An Bras Dermatol"},{"key":"4300_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14090","volume":"33","author":"MJ S\u00e1nchez-Pujol","year":"2020","unstructured":"S\u00e1nchez-Pujol MJ, Docampo-Sim\u00f3n A, Palaz\u00f3n-Cabanes JC, Betlloch I (2020) Alopecia universalis secondary to adalimumab treatment for psoriasis in a child. Dermatol Ther 33:e14090","journal-title":"Dermatol Ther"},{"key":"4300_CR27","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ibd\/izy112","volume":"24","author":"S Sridhar","year":"2018","unstructured":"Sridhar S, Maltz RM, Boyle B, Kim SC (2018) Dermatological manifestations in pediatric patients with inflammatory bowel diseases on anti-TNF therapy. Inflamm Bowel Dis 24:2086\u20132092","journal-title":"Inflamm Bowel Dis"},{"key":"4300_CR28","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jaad.2014.03.005","volume":"70","author":"M Tauber","year":"2014","unstructured":"Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain P-D et al (2014) Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70:1146\u20131149","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4300_CR29","doi-asserted-by":"publisher","first-page":"13030\/qt79j1d2j","DOI":"10.5070\/D32111029286","volume":"21","author":"H Toda-Brito","year":"2015","unstructured":"Toda-Brito H, Lopes L, Soares-Almeida L, Filipe P (2015) Adalimumab-induced psoriatic alopecia\/alopecia areata-like reaction in a patient with Crohn\u2019s disease. Dermatol Online J 21(11):13030\/qt79j1d2jv","journal-title":"Dermatol Online J"},{"key":"4300_CR30","doi-asserted-by":"publisher","first-page":"175628482110531","DOI":"10.1177\/17562848211053112","volume":"14","author":"H Yanai","year":"2021","unstructured":"Yanai H, Amir Barak H, Ollech JE, Avni Biron I, Goren I, Snir Y et al (2021) Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic. Therap Adv Gastroenterol 14:17562848211053112","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04300-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T16:40:35Z","timestamp":1749228035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04300-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4300"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04300-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the local Institutional Review Board (0748-21-RMC) and registered with the Israel Ministry of Health. The study has been granted an exemption from requiring written informed consent by the institutional ethics committee of Rabin Medical Center. We have obtained written informed consent from parents\/legal guardians for all participants aged under 18 for the publication of the patients\u2019 photos.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"799"}}